Phico Therapeutics receives funding from CARB-X towards the development of engineered bacteriophage with SASP gene targeting Pseudomonas aeruginosa.
Cytophage announced the beginning of animal testing of their throat and nasal phage spray that targets the COVID-19 virus.
TechnoPhage announced the beginning of Phase I/IIa study of TP-102 phage therapy to treat Diabetic Foot Infections (DPI).
Synthetic bacteriophages with shortened genome created successfully by scientists from CEB – Centre of Biological Engineering, Braga in Portugal.
MarketsandMarkets Next Gen Microbiome and Probiotics 2021 will be held as a virtual conference. The event will be on the 25th and 26th of February 2021.